胶质母细胞瘤中失调的信号通路：分子机制与治疗靶点。
Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
机构信息
The Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, Medical School, Houston, Texas 77030, USA.
出版信息
Cancer Invest. 2012 Jan;30(1):48-56. doi: 10.3109/07357907.2011.630050.
Abstract
Glioblastoma multiforme (GBM) is the most malignant and aggressive type of brain tumor with an average life expectancy of less than 15 months. This is mostly due to the highly mutated genome of GBM, which is characterized by the deregulation of many key signaling pathways involving growth, proliferation, survival, and apoptosis. It is critical to explore novel diagnostic and therapeutic strategies that target these pathways to improve the treatment of malignant glioma in the future. This review summarizes the most common and important pathways that are highly mutated or deregulated in GBM and discusses potential therapeutic strategies targeting these pathways.
摘要
多形性胶质母细胞瘤（GBM）是最恶性和侵袭性的脑肿瘤，平均预期寿命不到 15 个月。这主要是由于 GBM 高度突变的基因组，其特征是涉及生长、增殖、存活和凋亡的许多关键信号通路的失调。探索针对这些通路的新型诊断和治疗策略对于改善恶性胶质瘤的治疗至关重要。本综述总结了 GBM 中高度突变或失调的最常见和最重要的通路，并讨论了针对这些通路的潜在治疗策略。
相似文献
1
Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.胶质母细胞瘤中失调的信号通路：分子机制与治疗靶点。
Cancer Invest. 2012 Jan;30(1):48-56. doi: 10.3109/07357907.2011.630050.
2
Molecular pathways and potential therapeutic targets in glioblastoma multiforme.胶质母细胞瘤中的分子途径和潜在治疗靶点。
Expert Rev Anticancer Ther. 2013 Nov;13(11):1307-18. doi: 10.1586/14737140.2013.852472.
3
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.胶质母细胞瘤的分子特征、靶向治疗及迄今为止的临床结果。
Cancer. 2015 Feb 15;121(4):502-16. doi: 10.1002/cncr.28968. Epub 2014 Sep 23.
4
SnapShot: glioblastoma multiforme.简讯：多形性胶质母细胞瘤
Cancer Cell. 2012 May 15;21(5):710-710.e1. doi: 10.1016/j.ccr.2012.04.031.
5
The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy.Myc与let-7a在胶质母细胞瘤、葡萄糖代谢及治疗反应中的作用。
Arch Biochem Biophys. 2015 Aug 15;580:84-92. doi: 10.1016/j.abb.2015.07.005. Epub 2015 Jul 4.
6
Transcription factors in glioblastoma - Molecular pathogenesis and clinical implications.胶质母细胞瘤中的转录因子——分子发病机制及临床意义
Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188667. doi: 10.1016/j.bbcan.2021.188667. Epub 2021 Dec 8.
7
Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway.天然产物作为多形性胶质母细胞瘤的有前途的靶点：聚焦于 NF-κB 信号通路。
Pharmacol Rep. 2020 Apr;72(2):285-295. doi: 10.1007/s43440-020-00081-7. Epub 2020 Mar 9.
8
Targeting metabolic remodeling in glioblastoma multiforme.针对多形性胶质母细胞瘤中的代谢重塑
Oncotarget. 2010 Nov;1(7):552-62. doi: 10.18632/oncotarget.190.
9
Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.联合表达分析、生物信息学和靶向蛋白质组学鉴定胶质母细胞瘤干细胞中的新潜在治疗靶点。
Oncotarget. 2015 Sep 22;6(28):26192-215. doi: 10.18632/oncotarget.4613.
10
Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy.利用异常细胞信号通路在多形性胶质母细胞瘤中的作用：靶向治疗的前景。
Mol Biol Rep. 2024 Oct 19;51(1):1069. doi: 10.1007/s11033-024-09996-3.
引用本文的文献
1
Targeting TXN1 Induces G2M Phase Arrest and Apoptosis of Glioma Cells Through P38 MAPK Pathway.靶向TXN1通过P38丝裂原活化蛋白激酶途径诱导胶质瘤细胞的G2/M期阻滞和凋亡。
Appl Biochem Biotechnol. 2025 Aug 20. doi: 10.1007/s12010-025-05341-x.
2
Nanocomposite biosensor tracks honokiol-induced oxidative stress dynamics in 3D hydrogel-cultured lung cancer cells.纳米复合生物传感器追踪厚朴酚诱导的三维水凝胶培养肺癌细胞中的氧化应激动态。
Microsyst Nanoeng. 2025 Aug 14;11(1):154. doi: 10.1038/s41378-025-01016-z.
3
A Study on the Levels of Selected Proangiogenic Proteins in Human Tissues and Plasma in Relation to Brain Glioma.一项关于人体组织和血浆中特定促血管生成蛋白水平与脑胶质瘤关系的研究。
Int J Mol Sci. 2025 May 16;26(10):4802. doi: 10.3390/ijms26104802.
4
EMB-driven glioblastoma multiforme progression via the MCT4/GPX3 axis: therapeutic inhibition by Ganxintriol A.通过MCT4/GPX3轴由EMB驱动的多形性胶质母细胞瘤进展：甘辛三醇A的治疗性抑制作用
J Transl Med. 2025 Mar 4;23(1):272. doi: 10.1186/s12967-025-06290-z.
5
The subventricular zone structure, function and implications for neurological disease.脑室下区的结构、功能及其对神经系统疾病的影响。
Genes Dis. 2024 Aug 26;12(3):101398. doi: 10.1016/j.gendis.2024.101398. eCollection 2025 May.
6
The role of lncRNAs in the interplay of signaling pathways and epigenetic mechanisms in glioma.长链非编码RNA在神经胶质瘤信号通路与表观遗传机制相互作用中的作用
Epigenomics. 2025 Feb;17(2):125-140. doi: 10.1080/17501911.2024.2442297. Epub 2025 Jan 19.
7
Casein Kinase 2 Inhibitor, CX-4945, Induces Apoptosis and Restores Blood-Brain Barrier Homeostasis in In Vitro and In Vivo Models of Glioblastoma.酪蛋白激酶2抑制剂CX-4945在胶质母细胞瘤的体外和体内模型中诱导细胞凋亡并恢复血脑屏障稳态。
Cancers (Basel). 2024 Nov 24;16(23):3936. doi: 10.3390/cancers16233936.
8
Pan-Cancer Analysis of PTBP1 to Identify it as a Prognostic and Immunological Biomarker.泛癌症分析 PTBP1，鉴定其为预后和免疫生物标志物。
Cancer Control. 2024 Jan-Dec;31:10732748241302865. doi: 10.1177/10732748241302865.
9
hsa-miR-181a-5p inhibits glioblastoma development via the MAPK pathway: and study.hsa-miR-181a-5p 通过 MAPK 通路抑制胶质母细胞瘤的发展：一项临床和实验研究。
Oncol Res. 2024 Nov 13;32(12):1949-1958. doi: 10.32604/or.2024.051569. eCollection 2024.
10
Regulation of autophagy by non-coding RNAs in human glioblastoma.非编码 RNA 调控人胶质母细胞瘤中的自噬作用。
Med Oncol. 2024 Oct 7;41(11):260. doi: 10.1007/s12032-024-02513-3.
本文引用的文献
1
mTOR: from growth signal integration to cancer, diabetes and ageing.mTOR：从生长信号整合到癌症、糖尿病和衰老。
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. doi: 10.1038/nrm3025. Epub 2010 Dec 15.
2
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.北美癌症治疗组 N057K 期临床试验：雷帕霉素（RAD001）联合替莫唑胺治疗新诊断的多形性胶质母细胞瘤的疗效。
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):468-75. doi: 10.1016/j.ijrobp.2010.05.064. Epub 2010 Sep 23.
3
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.接受酶诱导型抗癫痫药物、标准放疗和替莫唑胺治疗的新诊断胶质母细胞瘤患者中，贝伐珠单抗（PTK787）的 I 期临床试验及生物标志物研究。
J Neurooncol. 2011 Jun;103(2):325-32. doi: 10.1007/s11060-010-0390-7. Epub 2010 Sep 7.
4
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.贝伐珠单抗联合厄洛替尼治疗复发性恶性脑胶质瘤的Ⅱ期临床试验
Neuro Oncol. 2010 Dec;12(12):1300-10. doi: 10.1093/neuonc/noq099. Epub 2010 Aug 17.
5
A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.贝伐珠单抗单药每 3 周方案治疗复发性高级别胶质瘤患者的 2 期临床试验。
Cancer. 2010 Nov 15;116(22):5297-305. doi: 10.1002/cncr.25462.
6
Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies.胶质母细胞瘤肿瘤干细胞：异质性、微环境及相关治疗策略。
Cell Biochem Funct. 2010 Jul;28(5):343-51. doi: 10.1002/cbf.1666.
7
Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology.美国原发性脑肿瘤的年龄、性别、行为和组织学分布的流行率估计。
Neuro Oncol. 2010 Jun;12(6):520-7. doi: 10.1093/neuonc/nop066. Epub 2010 Feb 8.
8
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.吉非替尼治疗新诊断为 4 级星形细胞瘤患者的 II 期评估：梅奥/中北部癌症治疗组研究 N0074。
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):347-53. doi: 10.1016/j.ijrobp.2010.01.070. Epub 2010 May 25.
9
mTOR signaling in glioblastoma: lessons learned from bench to bedside.mTOR 信号通路在胶质母细胞瘤中的作用：从实验室到临床的经验教训。
Neuro Oncol. 2010 Aug;12(8):882-9. doi: 10.1093/neuonc/noq052. Epub 2010 May 14.
10
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.西地尼布（cediranib）是一种口服的泛血管内皮生长因子受体酪氨酸激酶抑制剂，在复发性胶质母细胞瘤患者中的 II 期研究。
J Clin Oncol. 2010 Jun 10;28(17):2817-23. doi: 10.1200/JCO.2009.26.3988. Epub 2010 May 10.
Zotero 插件